Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 10/20 | 0.46 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.45 |
| ▸ | TACR1 | P25103 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | JAK1 | P23458 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | YAP1 | P46937 | 2/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | HTR6 | P50406 | 1/20 | 0.38 |
| ▸ | MMP9 | P14780 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31588721 | 1.00 | GPR119 (0.46) | GPR119USP30TACR1JAK2JAK1 | |
| SCHEMBL29440520 | 0.93 | USP30 (0.47) | GPR119USP30TACR1JAK2JAK1 | |
| SCHEMBL23761156 | 0.93 | USP30 (0.47) | GPR119USP30TACR1JAK2JAK1 | |
| SCHEMBL28933854 | 0.93 | USP30 (0.47) | GPR119USP30TACR1JAK2JAK1 | |
| SCHEMBL22765049 | 0.93 | USP30 (0.47) | GPR119USP30TACR1JAK2JAK1 | |
| SCHEMBL29440529 | 0.91 | GPR119 (0.49) | GPR119USP30TACR1JAK2JAK1 | |
| SCHEMBL29440530 | 0.91 | GPR119 (0.49) | GPR119USP30TACR1JAK2JAK1 | |
| SCHEMBL22764729 | 0.91 | GPR119 (0.49) | GPR119USP30TACR1JAK2JAK1 | |
| SCHEMBL24478310 | 0.91 | GPR119 (0.49) | GPR119USP30TACR1JAK2JAK1 | |
| SCHEMBL28690467 | 0.91 | GPR119 (0.49) | GPR119USP30TACR1JAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250179055-A1 | Substituted 2-(pyrrolidine-3-yl)acetic acid derivative, preparation method and use thereof | INNOVSTONE THERAPEUTICS LIMITED (CN) | 2025-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250179055-A1 | Substituted 2-(pyrrolidine-3-yl)acetic acid derivative, preparation method and use thereof | PCSK9, LPL, LYPLA1 | GPR119 474/4885USP30 2453/4885TACR1 2153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.